Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)

被引：1

作者：

Morgans, A. K. ^{[1
]}

Gschwend, J. E. ^{[2
]}

Shore, N. D. ^{[3
]}

Ross, A. ^{[4
]}

Feng, F. ^{[5
]}

Hope, T. ^{[6
]}

Trandafir, L. ^{[7
]}

Le Berre, M-A. ^{[8
]}

Kuss, I. ^{[9
]}

Joensuu, H. ^{[10
]}

Fizazi, K. ^{[11
]}

机构：

[1] Dana Farber Canc Inst, Med Dept, Boston, MA USA

[2] Tech Univ Munich, Dept Urol, Klinikum Rechts Isar, Munich, Germany

[3] GenesisCare US, Uro Oncol Dept, Carolina Urol Res Ctr, Myrtle Beach, SC USA

[4] Northwestern Univ, Urol, Feinberg Sch Med, Chicago, IL USA

[5] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Radiat Oncol, San Francisco, CA USA

[6] Univ Calif San Francisco, Radiol Sch Med, San Francisco, CA USA

[7] Bayer Consumer Care AG, R&D Dept, Basel, Switzerland

[8] Bayer Healthcare France, Biometry, Loos, France

[9] Bayer AG, Clin Dev SBU Oncol, Berlin, Germany

[10] Orion Corp, Orion Pharma, Espoo, Finland

[11] Univ Paris Saclay, Dept Canc Med, Gustave Roussy, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2789

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

184TiP

引用

页码：S997 / S998

页数：2

共 50 条

[21] Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
Yamamoto, Yutaka
Kiba, Keisuke
Yoshikawa, Motokiyo
Hirayama, Akihide
Kunikata, Seiji
Uemura, Hirotsugu
RESEARCH AND REPORTS IN UROLOGY, 2016, 8 : 225 - 231
[22] Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study
Taplin, Mary-Ellen
Montgomery, Bruce
Logothetis, Christopher J.
Bubley, Glenn J.
Richie, Jerome P.
Dalkin, Bruce L.
Sanda, Martin G.
Davis, John W.
Loda, Massimo
True, Lawrence D.
Troncoso, Patricia
Ye, Huihui
Lis, Rosina T.
Marck, Brett T.
Matsumoto, Alvin M.
Balk, Steven P.
Mostaghel, Elahe A.
Penning, Trevor M.
Nelson, Peter S.
Xie, Wanling
Jiang, Zhenyang
Haqq, Christopher M.
Tamae, Daniel
NamPhuong Tran
Peng, Weimin
Thian Kheoh
Molina, Arturo
Kantoff, Philip W.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) : 3705 - +
[23] A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE).
Haresh, K. P.
Vjaters, Egils
Castellano, Daniel
Olmos, David
Shore, Neal D.
Nevalaita, Liina
Testa, Isabella
Kappeler, Christian
Kuss, Iris
Saad, Fred
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[24] PATIENT REPORTED OUTCOMES (PROS) IN SPARTAN, A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF APALUTAMIDE (APA) PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VS PLACEBO PLUS ADT IN MEN WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)
Small, Eric J.
Saad, Fred
Hadaschik, Boris A.
Graff, Julie N.
Mainwaring, Paul N.
McQuarrie, Kelly
Li, Susan
Lawson, Joe
Lopez-Gitlitz, Angela
Smith, Matthew R.
JOURNAL OF UROLOGY, 2018, 199 (04): : E703 - E704
[25] Estrogen plus progestin therapy and cognition: A randomized placebo-controlled double-blind study
Alhola, Paula
Tuomisto, Hanna
Saarinen, Reetta
Portin, Raija
Kalleinen, Nea
Polo-Kantola, Paivi
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2010, 36 (04) : 796 - 802
[26] Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Armstrong, A. J.
Iguchi, T.
Azad, A. A.
Szmulewitz, R. Z.
Holzbeierlein, J.
Villers, A.
Alcaraz, A.
Alekseev, B. Y.
Shore, N. D.
Petrylak, D. P.
Rosbrook, B.
Zohren, F.
Yamada, S.
Haas, G. P.
Stenzl, A.
ANNALS OF ONCOLOGY, 2021, 32 : S1300 - S1301
[27] LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer
Fizazi, Karim
Tran, Namphuong
Fein, Luis Enrique
Matsubara, Nobuaki
Antolin, Alfredo Rodriguez
Alekseev, Boris Y.
Ozguroglu, Mustafa
Ye, Dingwei
Feyerabend, Susan
Protheroe, Andrew
De Porre, Peter
Kheoh, Thian
Park, Youn C.
Todd, Mary Beth
Chi, Kim N.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study
Gratzke, C. J.
Ozguroglu, M.
Peer, A.
Sendur, M. A. N.
Retz, M.
Goh, J. C. H.
Loidl, W. C.
Jayram, G.
Byun, S-S.
Kwak, C.
Kwiatkowski, M.
Kopp, R. Manneh
Limon, J. C. Vazquez
Penagos, J. F. Escobar
De Giorgi, U. F. F.
Trindade, K. M. D.
Niu, C.
Liu, Y.
Poehlein, C. H.
Rodriguez, J. M. Piulats
ANNALS OF ONCOLOGY, 2023, 34 : S957 - S958
[29] Timing of androgen-deprivation therapy and radical radiotherapy in localized prostate cancer: a phase III randomized controlled trial
Nieder, Carsten
STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (08) : 738 - 739
[30] Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
Hussain, Maha
Tombal, Bertrand
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, E. David
Shore, Neal
Kopyltsov, Evgeny
Kalebasty, Arash Rezazadeh
Boegemann, Martin
Ye, Dingwei
Cruz, Felipe
Suzuki, Hiroyoshi
Kapur, Shivani
Srinivasan, Shankar
Verholen, Frank
Kuss, Iris
Joensuu, Heikki
Smith, Matthew R.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (20) : 3595 - +

← 1 2 3 4 5 →